| Drug Name |
Alitretinoin |
| Drug ID |
BADD_D00075 |
| Description |
An important regulator of gene expression during growth and development, and in neoplasms. Tretinoin, also known as retinoic acid and derived from maternal vitamin A, is essential for normal growth; and embryonic development. An excess of tretinoin can be teratogenic. It is used in the treatment of psoriasis; acne vulgaris; and several other skin diseases. It has also been approved for use in promyelocytic leukemia (leukemia, promyelocytic, acute). |
| Indications and Usage |
For topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. |
| Marketing Status |
approved; investigational |
| ATC Code |
D11AH04; L01XF02 |
| DrugBank ID |
DB00523
|
| KEGG ID |
D02815
|
| MeSH ID |
D000077556
|
| PubChem ID |
449171
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
17337-0007; 59212-601; 17337-0008 |
| UNII |
1UA8E65KDZ
|
| Synonyms |
Alitretinoin | 9cRA Compound | 9-cis-Retinoic Acid | 9 cis Retinoic Acid | BAL4079 | Panretin | Toctino |
